Free Trial

ICU Medical (ICUI) Stock Price, News & Analysis

-2.61 (-2.50%)
(As of 05/24/2024 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
218,100 shs
Average Volume
247,620 shs
Market Capitalization
$2.48 billion
P/E Ratio
Dividend Yield
Price Target

ICU Medical MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
21.0% Upside
$123.00 Price Target
Short Interest
5.57% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.71mentions of ICU Medical in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$2.79 M Sold Last Quarter
Proj. Earnings Growth
From $3.50 to $5.10 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.01 out of 5 stars

Medical Sector

184th out of 921 stocks

Surgical & Medical Instruments Industry

26th out of 97 stocks

ICUI stock logo

About ICU Medical Stock (NASDAQ:ICUI)

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

ICUI Stock Price History

ICUI Stock News Headlines

ICU Medical Announces First Quarter 2024 Results
ICU Medical earnings: here's what to expect
ICU Medical Q1 2024 Earnings Preview
ICUI Apr 2024 60.000 put
ICU Medical Inc ICUI
ICUI Apr 2024 80.000 put
ICUI Apr 2024 125.000 call
ICUI Apr 2024 120.000 call
See More Headlines
Receive ICUI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICU Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Supplies
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$2.26 billion
Cash Flow
$15.31 per share
Book Value
$87.96 per share


Free Float
Market Cap
$2.48 billion

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

ICUI Stock Analysis - Frequently Asked Questions

Should I buy or sell ICU Medical stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ICU Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ICUI shares.
View ICUI analyst ratings
or view top-rated stocks.

What is ICU Medical's stock price target for 2024?

2 analysts have issued 1 year price objectives for ICU Medical's shares. Their ICUI share price targets range from $110.00 to $136.00. On average, they predict the company's stock price to reach $123.00 in the next twelve months. This suggests a possible upside of 21.0% from the stock's current price.
View analysts price targets for ICUI
or view top-rated stocks among Wall Street analysts.

How have ICUI shares performed in 2024?

ICU Medical's stock was trading at $99.74 at the start of the year. Since then, ICUI shares have increased by 1.9% and is now trading at $101.68.
View the best growth stocks for 2024 here

When is ICU Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our ICUI earnings forecast

How were ICU Medical's earnings last quarter?

ICU Medical, Inc. (NASDAQ:ICUI) released its quarterly earnings data on Tuesday, May, 7th. The medical instruments supplier reported $0.60 EPS for the quarter, beating the consensus estimate of $0.54 by $0.06. The medical instruments supplier had revenue of $566.66 million for the quarter, compared to analyst estimates of $553.15 million. ICU Medical had a negative net margin of 2.63% and a positive trailing twelve-month return on equity of 5.38%.

What ETFs hold ICU Medical's stock?
What guidance has ICU Medical issued on next quarter's earnings?

ICU Medical updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of 4.400-5.100 for the period, compared to the consensus earnings per share estimate of 4.730. The company issued revenue guidance of -.

What is Vivek Jain's approval rating as ICU Medical's CEO?

81 employees have rated ICU Medical Chief Executive Officer Vivek Jain on Vivek Jain has an approval rating of 73% among the company's employees.

What other stocks do shareholders of ICU Medical own?
Who are ICU Medical's major shareholders?

ICU Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (10.14%), Vanguard Group Inc. (10.07%), Silvercrest Asset Management Group LLC (1.14%), WCM Investment Management LLC (1.05%), Mesirow Institutional Investment Management Inc. (0.59%) and Allspring Global Investments Holdings LLC (0.37%). Insiders that own company stock include Ben Sousa, Christian B Voigtlander, Daniel Woolson, Elisha W Finney, George A Lopez, Virginia Ruth Sanzone and Vivek Jain.
View institutional ownership trends

How do I buy shares of ICU Medical?

Shares of ICUI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ICUI) was last updated on 5/27/2024 by Staff

From Our Partners